Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Status:
Recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.

Phase 4

Pfizer

Crizotinib